Arch Therapeutics, Inc. (OTCMKTS:ARTH – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 14,600 shares, a growth of 16.8% from the October 15th total of 12,500 shares. Based on an average trading volume of 18,200 shares, the short-interest ratio is currently 0.8 days.
Arch Therapeutics Stock Down 11.3 %
OTCMKTS:ARTH traded down $0.03 during trading hours on Friday, hitting $0.25. 14,496 shares of the company were exchanged, compared to its average volume of 8,407. Arch Therapeutics has a 52-week low of $0.17 and a 52-week high of $18.00. The company’s 50 day moving average price is $0.42 and its 200-day moving average price is $0.74.
Arch Therapeutics (OTCMKTS:ARTH – Get Free Report) last announced its quarterly earnings data on Monday, August 19th. The biotechnology company reported ($1.44) earnings per share for the quarter. The firm had revenue of $0.03 million for the quarter.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.
Read More
- Five stocks we like better than Arch Therapeutics
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Top-Performing Non-Leveraged ETFs This Year
- Do ETFs Pay Dividends? What You Need to Know
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- Roth IRA Calculator: Calculate Your Potential Returns
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
